Omapro Needs Companion Diagnostic, Advisory Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
ChemGenex must determine which chronic myeloid leukemia patients have the T351I mutation and could benefit from the drug.
You may also be interested in...
Teva’s Synribo Clears FDA For Third-Line Chronic Myeloid Leukemia
Omacetaxine, which was originally submitted by ChemGenex as Omapro, demonstrated response rates of 14% to 18% in patients who had failed two or more tyrosine kinase inhibitors. It enters a crowded space that is likely to add a new member, Ariad’s ponatinib, in the coming months.
No Additional Omapro Trials Needed, FDA Tells ChemGenex In Complete Response Letter
FDA reservations mirror those outlined about need for validated assay test at March 22 ODAC meeting.
No Additional Omapro Trials Needed, FDA Tells ChemGenex In Complete Response Letter
FDA reservations mirror those outlined about need for validated assay test at March 22 ODAC meeting.